The end for genital human papillomavirus infections?
Stanley
Margaret
M
D000914:Antibodies, Viral / Q000096:biosynthesis; D036022:Capsid Proteins; D017322:Clinical Trials, Phase II as Topic; D005260:Female; D052776:Female Urogenital Diseases / Q000382:microbiology* / Q000517:prevention & control*; D006801:Humans; D008297:Male; D052801:Male Urogenital Diseases; D009856:Oncogene Proteins, Viral / Q000276:immunology; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000517:prevention & control*; D014412:Tumor Virus Infections / Q000517:prevention & control*; D014765:Viral Vaccines / Q000627:therapeutic use*
D000914:Antibodies, Viral; D036022:Capsid Proteins; C114580:HPV L1 protein, Human papillomavirus; D009856:Oncogene Proteins, Viral; D014765:Viral Vaccines